{"id":1725,"date":"2016-12-22T12:33:24","date_gmt":"2016-12-22T12:33:24","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1725"},"modified":"2021-10-12T08:47:03","modified_gmt":"2021-10-12T03:17:03","slug":"pharma-ma-rebound-may-take-a-while-in-2017","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-ma-rebound-may-take-a-while-in-2017","title":{"rendered":"Pharma M&#038;A Rebound May Take a While in 2017"},"content":{"rendered":"<p style=\"text-align: justify;\">The only word that described 2016\u2019s pharma M&amp;A market was \u201cslow.\u201d Some do predict that new year\u2014and administration\u2014could revive energy in the deal making arena, the changes might not happen that fast. The reasons are aplenty, as shares have been sagging under the weight of investor fears of drug-pricing reform. Companies aren\u2019t all that keen on putting themselves up for sale while valuations are low. Drug pricing is inhibiting M&amp;A in another way, too. Specialty drug makers have drawn unwanted attention since last summer with their buy-and-hike-prices strategy. In the meantime, they\u2019ve been shying away from the deal making table, fearing they&#8217;d become the next Valeant, Turing or Mylan in the spotlight. Thus, the new regime under Donald Trump might blow life into the M&amp;A activities, but this might take time and visible results might take a while.<\/p>\n<p style=\"text-align: justify;\">To know more, click <a href=\"http:\/\/www.fiercepharma.com\/node\/364146\">Pharma M&amp;A<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The only word that described 2016\u2019s pharma M&amp;A market was \u201cslow.\u201d Some do predict that new year\u2014and administration\u2014could revive energy in the deal making arena, the changes might not happen that fast. The reasons are aplenty, as shares have been sagging under the weight of investor fears of drug-pricing reform. Companies aren\u2019t all that keen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1033,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[713,715,717,716,711,620,714,712],"industry":[17225],"therapeutic_areas":[],"class_list":["post-1725","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-713","tag-acquisition","tag-collaboration","tag-funding","tag-ma","tag-merger","tag-new-year","tag-pharma-industry","industry-pharmaceutical"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma M&amp;A Rebound May Take a While in 2017 | DelveInsight<\/title>\n<meta name=\"description\" content=\"The only word that described 2016\u2019s pharma M&amp;A market was \u201cslow.\u201d Some do predict that new year\u2014and administration\u2014could revive energy in the deal...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-ma-rebound-may-take-a-while-in-2017\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma M&amp;A Rebound May Take a While in 2017 | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The only word that described 2016\u2019s pharma M&amp;A market was \u201cslow.\u201d Some do predict that new year\u2014and administration\u2014could revive energy in the deal...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-ma-rebound-may-take-a-while-in-2017\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-12-22T12:33:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-12T03:17:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"256\" \/>\n\t<meta property=\"og:image:height\" content=\"196\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma M&A Rebound May Take a While in 2017 | DelveInsight","description":"The only word that described 2016\u2019s pharma M&A market was \u201cslow.\u201d Some do predict that new year\u2014and administration\u2014could revive energy in the deal...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-ma-rebound-may-take-a-while-in-2017","og_locale":"en_US","og_type":"article","og_title":"Pharma M&A Rebound May Take a While in 2017 | DelveInsight","og_description":"The only word that described 2016\u2019s pharma M&A market was \u201cslow.\u201d Some do predict that new year\u2014and administration\u2014could revive energy in the deal...","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-ma-rebound-may-take-a-while-in-2017","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-12-22T12:33:24+00:00","article_modified_time":"2021-10-12T03:17:03+00:00","og_image":[{"width":256,"height":196,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-ma-rebound-may-take-a-while-in-2017","url":"https:\/\/www.delveinsight.com\/blog\/pharma-ma-rebound-may-take-a-while-in-2017","name":"Pharma M&A Rebound May Take a While in 2017 | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-ma-rebound-may-take-a-while-in-2017#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-ma-rebound-may-take-a-while-in-2017#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","datePublished":"2016-12-22T12:33:24+00:00","dateModified":"2021-10-12T03:17:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The only word that described 2016\u2019s pharma M&A market was \u201cslow.\u201d Some do predict that new year\u2014and administration\u2014could revive energy in the deal...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-ma-rebound-may-take-a-while-in-2017"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-ma-rebound-may-take-a-while-in-2017#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","width":256,"height":196},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">2017<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Acquisition<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Collaboration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Funding<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">M&amp;A<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Merger<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">New Year<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">2017<\/span>","<span class=\"advgb-post-tax-term\">Acquisition<\/span>","<span class=\"advgb-post-tax-term\">Collaboration<\/span>","<span class=\"advgb-post-tax-term\">Funding<\/span>","<span class=\"advgb-post-tax-term\">M&amp;A<\/span>","<span class=\"advgb-post-tax-term\">Merger<\/span>","<span class=\"advgb-post-tax-term\">New Year<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 22, 2016","modified":"Updated on Oct 12, 2021"},"absolute_dates_time":{"created":"Posted on Dec 22, 2016 12:33 pm","modified":"Updated on Oct 12, 2021 8:47 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1725"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1725\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1033"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1725"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1725"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}